Dr. Kunz on the Impact of Lanreotide's Approval for Neuroendocrine Tumors

Pamela L. Kunz
Published: Friday, Jan 16, 2015



Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide on the overall treatment paradigm for patients with neuroendocrine tumors.

The approval gave creditability to the use of somatostatin analogs as antiproliferative agents, Kunz says. Many oncologists have long been using the somatostatin analog octreotide as an antiproliferative agent for the treatment of small bowel neuroendocrine tumors, despite it not having FDA label for that use, Kunz suggests.

As a result of lanreotide (Somatuline Depot) being applied to a larger patient population in the CLARINET study, Kunz says many oncologists are expanding the patient population for which they consider somatostatin analogs as antiproliferative agents.

<<< View more from the 2015 GI Cancer Symposium



Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses the impact of the approval of lanreotide on the overall treatment paradigm for patients with neuroendocrine tumors.

The approval gave creditability to the use of somatostatin analogs as antiproliferative agents, Kunz says. Many oncologists have long been using the somatostatin analog octreotide as an antiproliferative agent for the treatment of small bowel neuroendocrine tumors, despite it not having FDA label for that use, Kunz suggests.

As a result of lanreotide (Somatuline Depot) being applied to a larger patient population in the CLARINET study, Kunz says many oncologists are expanding the patient population for which they consider somatostatin analogs as antiproliferative agents.

<<< View more from the 2015 GI Cancer Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x